PEA and luteolin synergistically reduce mast cell-mediated toxicity and elicit neuroprotection in cell-based models of brain ischemia

Brain Research

Volumn 1648, Issue , 2016, Pages 409-417

  Parrella, Edoardo ^a   Porrini, Vanessa ^a   Iorio, Rosa ^a   Benarese, Marina ^a   Lanzillotta, Annamaria ^a   Mota, Mariana ^a   Fusco, Mariella ^c   Tonin, Paolo ^b   Spano, PierFranco ^a,b   Pizzi, Marina ^a,b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b IRCCS SAN CAMILLO HOSPITAL   (Italy)

^c La Giulia Group Srl   (Italy)

Author keywords

Brain ischemia; Luteolin; Mast cells; Neuroinflammation; Neurons; PEA

Indexed keywords

GLUCOSE; LACTATE DEHYDROGENASE; LUTEOLIN; OXYGEN; PALMIDROL; ETHANOLAMINE DERIVATIVE; NEUROPROTECTIVE AGENT; PALMITIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; BRAIN ISCHEMIA; CELL DAMAGE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG POTENTIATION; FETUS LIVER; MAST CELL DEGRANULATION; MOUSE; NERVE CELL CULTURE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CELL CULTURE; COCULTURE; DEGRANULATION; DRUG EFFECTS; MAST CELL; METABOLISM; NERVE CELL; PHYSIOLOGY;

ANIMALS; BRAIN ISCHEMIA; CELL DEGRANULATION; CELLS, CULTURED; COCULTURE TECHNIQUES; ETHANOLAMINES; GLUCOSE; L-LACTATE DEHYDROGENASE; LUTEOLIN; MAST CELLS; MICE; MICE, INBRED C57BL; NEURONS; NEUROPROTECTIVE AGENTS; OXYGEN; PALMITIC ACIDS;

EID: 84982111762     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2016.07.014     Document Type: Article

References (64)

1. Ahmad, A., Genovese, T., Impellizzeri, D., Crupi, R., Velardi, E., Marino, A., Esposito, E., Cuzzocrea, S., Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats. Brain Res. 1477 (2012), 45–58.
2. Attoub, S., Hassan, A.H., Vanhoecke, B., Iratni, R., Takahashi, T., Gaben, A.M., Bracke, M., Awad, S., John, A., Kamalboor, H.A., Al Sultan, M.A., Arafat, K., Gespach, C., Petroianu, G., Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells. Eur. J. Pharmacol. 651 (2011), 18–25.
3. Barbierato, M., Facci, L., Marinelli, C., Zusso, M., Argentini, C., Skaper, S.D., Giusti, P., Co-ultramicronized palmitoylethanolamide/luteolin promotes the maturation of oligodendrocyte precursor cells. Sci. Rep., 5, 2015, 16676.
4. Caltagirone, C., Cisari, C., Schievano, C., Di Paola, R., Cordaro, M., Bruschetta, G., Esposito, E., Cuzzocrea, S., Co-ultramicronized palmitoylethanolamide/luteolin in the treatment of cerebral ischemia: from rodent to man. Transl. Stroke Res., 2015.
5. Christy, A.L., Brown, M.A., The multitasking mast cell: positive and negative roles in the progression of autoimmunity. J. Immunol. 179 (2007), 2673–2679.
6. Cordaro, M., Impellizzeri, D., Paterniti, I., Bruschetta, G., Siracusa, R., De Stefano, D., Cuzzocrea, S., Esposito, E., Neuroprotective effects of Co-ultraPEALut on secondary inflammatory process and autophagy involved in traumatic brain injury. J. Neurotrauma 33:1 (2015), 132–146.
7. Crupi, R., Paterniti, I., Ahmad, A., Campolo, M., Esposito, E., Cuzzocrea, S., Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression. CNS Neurol. Disord. Drug Targets 12 (2013), 989–1001.
8. D'Agostino, G., Russo, R., Avagliano, C., Cristiano, C., Meli, R., Calignano, A., Palmitoylethanolamide protects against the amyloid-beta25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. Neuropsychopharmacology 37 (2012), 1784–1792.
9. Dajas, F., Rivera-Megret, F., Blasina, F., Arredondo, F., Abin-Carriquiry, J.A., Costa, G., Echeverry, C., Lafon, L., Heizen, H., Ferreira, M., Morquio, A., Neuroprotection by flavonoids. Braz. J. Med. Biol. Res. 36 (2003), 1613–1620.
10. De Filippis, D., Luongo, L., Cipriano, M., Palazzo, E., Cinelli, M.P., de Novellis, V., Maione, S., Iuvone, T., Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. Mol. Pain, 7, 2011, 3.
11. De Filippis, D., Negro, L., Vaia, M., Cinelli, M.P., Iuvone, T., New insights in mast cell modulation by palmitoylethanolamide. CNS Neurol. Disord. Drug Targets 12 (2013), 78–83.
12. Dropp, J.J., Mast cells in the human brain. Acta Anat. 105 (1979), 505–513.
13. Esposito, E., Cordaro, M., Cuzzocrea, S., Roles of fatty acid ethanolamides (FAE) in traumatic and ischemic brain injury. Pharm. Res. 86 (2014), 26–31.
14. Esposito, E., Cuzzocrea, S., Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries. CNS Neurol. Disord. Drug Targets 12 (2013), 55–61.
15. Esposito, E., Impellizzeri, D., Mazzon, E., Paterniti, I., Cuzzocrea, S., Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease. PLoS One, 7, 2012, e41880.
16. Esposito, E., Paterniti, I., Mazzon, E., Genovese, T., Di Paola, R., Galuppo, M., Cuzzocrea, S., Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. Brain Behav. Immun. 25 (2011), 1099–1112.
17. Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S.D., Leon, A., Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA 92 (1995), 3376–3380.
18. Galli, S.J., Nakae, S., Tsai, M., Mast cells in the development of adaptive immune responses. Nat. Immunol. 6 (2005), 135–142.
19. Garg, P., Duncan, R.S., Kaja, S., Koulen, P., Intracellular mechanisms of N-acylethanolamine-mediated neuroprotection in a rat model of stroke. Neuroscience 166 (2010), 252–262.
20. Guerra-Araiza, C., Alvarez-Mejia, A.L., Sanchez-Torres, S., Farfan-Garcia, E., Mondragon-Lozano, R., Pinto-Almazan, R., Salgado-Ceballos, H., Effect of natural exogenous antioxidants on aging and on neurodegenerative diseases. Free Radic. Res. 47 (2013), 451–462.
21. Hansen, H.S., Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp. Neurol. 224 (2010), 48–55.
22. Henderson, W.R., Chi, E.Y., Klebanoff, S.J., Eosinophil peroxidase-induced mast cell secretion. J. Exp. Med. 152 (1980), 265–279.
23. Hu, W., Xu, L., Pan, J., Zheng, X., Chen, Z., Effect of cerebral ischemia on brain mast cells in rats. Brain Res. 1019 (2004), 275–280.
24. Hu, W., Shen, Y., Fu, Q., Dai, H., Tu, H., Wei, E., Luo, J., Chen, Z., Effect of oxygen-glucose deprivation on degranulation and histamine release of mast cells. Cell Tissue Res. 322 (2005), 437–441.
25. Impellizzeri, D., Esposito, E., Di Paola, R., Ahmad, A., Campolo, M., Peli, A., Morittu, V.M., Britti, D., Cuzzocrea, S., Palmitoylethanolamide and luteolin ameliorate development of arthritis caused by injection of collagen type II in mice. Arthritis Res Ther., 15, 2013, R192.
26. Impellizzeri, D., Ahmad, A., Bruschetta, G., Di Paola, R., Crupi, R., Paterniti, I., Esposito, E., Cuzzocrea, S., The anti-inflammatory effects of palmitoylethanolamide (PEA) on endotoxin-induced uveitis in rats. Eur. J. Pharmacol. 761 (2015), 28–35.
27. Jeon, I.H., Kim, H.S., Kang, H.J., Lee, H.S., Jeong, S.I., Kim, S.J., Jang, S.I., Anti-inflammatory and antipruritic effects of luteolin from Perilla (P. frutescens L.) leaves. Molecules 19 (2014), 6941–6951.
28. Jin, M., Son, K.H., Chang, H.W., Luteolin-7-O-glucoside suppresses leukotriene C(4) production and degranulation by inhibiting the phosphorylation of mitogen activated protein kinases and phospholipase Cgamma1 in activated mouse bone marrow-derived mast cells. Biol. Pharm. Bull. 34 (2011), 1032–1036.
29. Kawahara, T., Establishment and characterization of mouse bone marrow-derived mast cell hybridomas. Exp. Cell Res. 318 (2012), 2385–2396.
30. Kritas, S.K., Saggini, A., Varvara, G., Murmura, G., Caraffa, A., Antinolfi, P., Toniato, E., Pantalone, A., Neri, G., Frydas, S., Rosati, M., Tei, M., Speziali, A., Saggini, R., Pandolfi, F., Cerulli, G., Theoharides, T.C., Conti, P., Luteolin inhibits mast cell-mediated allergic inflammation. J. Biol. Regul. Homeost. Agents 27 (2013), 955–959.
31. Lanzillotta, A., Pignataro, G., Branca, C., Cuomo, O., Sarnico, I., Benarese, M., Annunziato, L., Spano, P., Pizzi, M., Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window. Neurobiol. Dis. 49C (2013), 177–189.
32. Lanzillotta, A., Sarnico, I., Ingrassia, R., Boroni, F., Branca, C., Benarese, M., Faraco, G., Blasi, F., Chiarugi, A., Spano, P., Pizzi, M., The acetylation of RelA in Lys310 dictates the NF-kappaB-dependent response in post-ischemic injury. Cell Death Dis., 1, 2010, e96.
33. Lin, Y., Shi, R., Wang, X., Shen, H.M., Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr. Cancer Drug Targets 8:7 (2008), 634–646.
34. Lindsberg, P.J., Strbian, D., Karjalainen-Lindsberg, M.L., Mast cells as early responders in the regulation of acute blood-brain barrier changes after cerebral ischemia and hemorrhage. J. Cereb. Blood Flow. Metab. 30 (2010), 689–702.
35. Lopez-Lazaro, M., Distribution and biological activities of the flavonoid luteolin. Mini Rev. Med. Chem. 9 (2009), 31–59.
36. LoVerme, J., Russo, R., La Rana, G., Fu, J., Farthing, J., Mattace-Raso, G., Meli, R., Hohmann, A., Calignano, A., Piomelli, D., Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J. Pharm. Exp. Ther. 319 (2006), 1051–1061.
37. Marshall, J.S., Mast-cell responses to pathogens. Nat. Rev. Immunol. 4 (2004), 787–799.
38. Masini, E., Palmerani, B., Gambassi, F., Pistelli, A., Giannella, E., Occupati, B., Ciuffi, M., Sacchi, T.B., Mannaioni, P.F., Histamine release from rat mast cells induced by metabolic activation of polyunsaturated fatty acids into free radicals. Biochem Pharmacol. 39 (1990), 879–889.
39. Mattila, O.S., Strbian, D., Saksi, J., Pikkarainen, T.O., Rantanen, V., Tatlisumak, T., Lindsberg, P.J., Cerebral mast cells mediate blood-brain barrier disruption in acute experimental ischemic stroke through perivascular gelatinase activation. Stroke 42 (2011), 3600–3605.
40. Metz, M., Grimbaldeston, M.A., Nakae, S., Piliponsky, A.M., Tsai, M., Galli, S.J., Mast cells in the promotion and limitation of chronic inflammation. Immunol. Rev. 217 (2007), 304–328.
41. Nelissen, S., Lemmens, E., Geurts, N., Kramer, P., Maurer, M., Hendriks, J., Hendrix, S., The role of mast cells in neuroinflammation. Acta Neuropathol. 125 (2013), 637–650.
42. Paterniti, I., Di Paola, R., Campolo, M., Siracusa, R., Cordaro, M., Bruschetta, G., Tremolada, G., Maestroni, A., Bandello, F., Esposito, E., Zerbini, G., Cuzzocrea, S., Palmitoylethanolamide treatment reduces retinal inflammation in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 769 (2015), 313–323.
43. Paterniti, I., Cordaro, M., Campolo, M., Siracusa, R., Cornelius, C., Navarra, M., Cuzzocrea, S., Esposito, E., Neuroprotection by association of palmitoylethanolamide with luteolin in experimental alzheimer's disease models: the control of neuroinflammation. CNS Neurol. Disord. Drug Targets, 2014.
44. Paterniti, I., Impellizzeri, D., Di Paola, R., Navarra, M., Cuzzocrea, S., Esposito, E., A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury. J. Neuroinflamm., 10, 2013, 91.
45. Qiao, H., Dong, L., Zhang, X., Zhu, C., Wang, L., Liu, Z., Chen, L., Xing, Y., Wang, C., Li, Y., Protective effect of luteolin in experimental ischemic stroke: upregulated SOD1, CAT, Bcl-2 and claudin-5, down-regulated MDA and Bax expression. Neurochem. Res. 37 (2012), 2014–2024.
46. Qiao, H., Zhang, X., Zhu, C., Dong, L., Wang, L., Xing, Y., Wang, C., Ji, Y., Cao, X., Luteolin downregulates TLR4, TLR5, NF-kappaB and p-p38MAPK expression, upregulates the p-ERK expression, and protects rat brains against focal ischemia. Brain Res. 1448 (2014), 71–81.
47. Sarnico, I., Lanzillotta, A., Boroni, F., Benarese, M., Alghisi, M., Schwaninger, M., Inta, I., Battistin, L., Spano, P., Pizzi, M., NF-kappaB p50/RelA and c-Rel-containing dimers: opposite regulators of neuron vulnerability to ischaemia. J. Neurochem. 108 (2009), 475–485.
48. Scuderi, C., Stecca, C., Valenza, M., Ratano, P., Bronzuoli, M.R., Bartoli, S., Steardo, L., Pompili, E., Fumagalli, L., Campolongo, P., Steardo, L., Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease. Cell Death Dis., 5, 2014, e1419.
49. Scuderi, C., Valenza, M., Stecca, C., Esposito, G., Carratu, M.R., Steardo, L., Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-alpha. J. Neuroinflamm., 9, 2012, 49.
50. Silver, R., Curley, J.P., Mast cells on the mind: new insights and opportunities. Trends Neurosci. 36 (2013), 513–521.
51. Silverman, A.J., Sutherland, A.K., Wilhelm, M., Silver, R., Mast cells migrate from blood to brain. J. Neurosci. 20 (2000), 401–408.
52. Siracusa, R., Paterniti, I., Impellizzeri, D., Cordaro, M., Crupi, R., Navarra, M., Cuzzocrea, S., Esposito, E., The association of palmitoylethanolamide with luteolin decreases neuroinflammation and stimulates autophagy in Parkinson's disease model. CNS Neurol. Disord. Drug Targets, 2015.
53. Skaper, S.D., Facci, L., Fusco, M., Della Valle, M.F., Zusso, M., Costa, B., Giusti, P., Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology 22 (2014), 79–94.
54. Skaper, S.D., Facci, L., Giusti, P., Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Mol. Neurobiol., 2013.
55. Skaper, S.D., Buriani, A., Dal Toso, R., Petrelli, L., Romanello, S., Facci, L., Leon, A., The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad. Sci. USA 93 (1996), 3984–3989.
56. Skaper, S.D., Facci, L., Romanello, S., Leon, A., Mast cell activation causes delayed neurodegeneration in mixed hippocampal cultures via the nitric oxide pathway. J. Neurochem. 66 (1996), 1157–1166.
57. Strbian, D., Karjalainen-Lindsberg, M.L., Tatlisumak, T., Lindsberg, P.J., Cerebral mast cells regulate early ischemic brain swelling and neutrophil accumulation. J. Cereb. Blood Flow. Metab. 26 (2006), 605–612.
58. Strbian, D., Kovanen, P.T., Karjalainen-Lindsberg, M.L., Tatlisumak, T., Lindsberg, P.J., An emerging role of mast cells in cerebral ischemia and hemorrhage. Ann. Med. 41 (2009), 438–450.
59. Taliou, A., Zintzaras, E., Lykouras, L., Francis, K., An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clin. Ther. 35 (2013), 592–602.
60. Theoharides, T.C., Asadi, S., Panagiotidou, S., A case series of a luteolin formulation (NeuroProtek(R)) in children with autism spectrum disorders. Int. J. Immunopathol. Pharmacol. 25 (2012), 317–323.
61. Theoharides, T.C., Asadi, S., Patel, A.B., Focal brain inflammation and autism. J. Neuroinflamm., 10, 2013, 46.
62. Theoharides, T.C., Mast cells: the immune gate to the brain. Life Sci. 46 (1990), 607–617.
63. Theoharides, T.C., Luteolin as a therapeutic option for multiple sclerosis. J. Neuroinflamm., 6, 2009, 29.
64. Zhao, G., Zang, S.Y., Jiang, Z.H., Chen, Y.Y., Ji, X.H., Lu, B.F., Wu, J.H., Qin, G.W., Guo, L.H., Postischemic administration of liposome-encapsulated luteolin prevents against ischemia-reperfusion injury in a rat middle cerebral artery occlusion model. J. Nutr. Biochem. 22 (2011), 929–936.